# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: K062746   
B. Purpose for Submission: New device   
C. Measurand: Ferritin   
D. Type of Test: Particle enhanced immunoturbidimetry   
E. Applicant: Medicon Hellas SA   
F. Proprietary and Established Names: Medicon Ferritin - LATEX   
G. Regulatory Information: 1. Regulation section: 21 CFR 866.5340 Ferritin immunological test system 2. Classification: Class II 3. Product code: DBF Ferritin, antigen, antiserum, control 4. Panel: Immunology (82)

# H. Intended Use:

1. Intended use(s): The Medicon Ferritin – LATEX is an in vitro diagnostic reagent intended for the determination of Ferritin in human serum and plasma using Olympus AU400/600/640 automated clinical chemistry analyzers.   
2. Indication(s) for use: Medicon Ferritin – LATEX reagent is for the determination of ferritin in human serum and plasma using automated clinical chemistry analyzers. The measurement of ferritin may aid in the diagnosis of diseases affecting iron metabolism.   
3. Special conditions for use statement(s): Prescription use   
4. Special instrument requirements: Olympus Clinical Chemistry Analyzers, Models AU400/600/640

# I. Device Description:

The Ferritin – LATEX reagents consist of R1: $1 2 0 \mathrm { n M }$ Tris buffer $\mathrm { p H } { = } 8 . 2$ , accelerator, surfactant, stabilizers and preservatives; and R2: latex particles coated with rabbit anti-human ferritin in $2 0 \mathrm { n M }$ Tris buffer $\mathrm { p H } { = } 8 . 4$ , stabilizers and preservatives.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Olympus Ferritin Reagent   
2. Predicate 510(k) number(s): k030124   
3. Comparison with predicate:

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">New DeviceMedicon Ferritin</td><td colspan="1" rowspan="1">PredicateOlympus Ferritink030124</td></tr><tr><td colspan="1" rowspan="1">Indication for use</td><td colspan="1" rowspan="1">Medicon Ferritin LATEX reagent is for thedetermination of ferritin inhuman serum and plasmausing automated clinicalchemistry analyzers. Themeasurement of ferritinmay aid in the diagnosis ofdiseases affecting ironmetabolism.</td><td colspan="1" rowspan="1">Reagent for thedetermination of ferritinconcentrations in humanserum using theOlympus family ofclinical chemistryanalyzers.Serum ferritin is anindicator of body ironstores: Measurements offerritin aid in thediagnosis of diseasesaffecting ironmetabolism, such ashemochromatosis (ironoverload) and irondeficiency anemia.</td></tr><tr><td colspan="1" rowspan="1">Constituents</td><td colspan="1" rowspan="1">Ferritin R1 (Buffer) Readyto UseFerritin R2 (Latex) Readyto Use</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Storage conditions</td><td colspan="1" rowspan="1">Refrigerate at 2 ° - 8° Cuntil expired</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Methodology</td><td colspan="1" rowspan="1">Particle enhancedimmunoturbidimetry</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Instrument family</td><td colspan="1" rowspan="1">Olympus ClinicalChemistry Analyzers</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Formulation</td><td colspan="1" rowspan="1">Final reactive ingredients:Tris Buffer pH: 8.2Latex particles coated withrabbit anti-human ferritinPreservative</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibrator -recommended but notincluded with kit</td><td colspan="1" rowspan="1">Olympus Serum ProteinMulti-CalibratorODR3021</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Controls recommended but notincluded with kit</td><td colspan="1" rowspan="1">Olympus ITA ControlSera, ODC0014,ODC0015, ODC0016</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagent Stability</td><td colspan="1" rowspan="1">On board: 30 days</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibration Interval</td><td colspan="1" rowspan="1">After each lot and 14 days</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reference Intervals</td><td colspan="1" rowspan="1">Serum / Plasma:Infants  1 month:6-400 ng/mL1 month - 6 months:6-410 ng/mL6 months  12 months:6-80 ng/mL1 year - 5 years:660 ng/mL6 years - 19 years:6320 ng/mLadult men: 20-250 ng/mLadult women:20-200ng/mL</td><td colspan="1" rowspan="1">Same (for serum only)</td></tr><tr><td colspan="1" rowspan="1">Traceability/Standardization</td><td colspan="1" rowspan="1">Standardized against theWHO 3rd InternationalStandard for ferritin,Recombinant NBSC code:94/572.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">New DeviceMedicon Ferritin</td><td colspan="1" rowspan="1">PredicateOlympus FerritinK030124</td></tr><tr><td colspan="1" rowspan="1">Measuring Range</td><td colspan="1" rowspan="1">4 - 450 ng/ml</td><td colspan="1" rowspan="1">8 - 450 ng/ml</td></tr><tr><td colspan="1" rowspan="1">Sample type</td><td colspan="1" rowspan="1">Serum and plasma</td><td colspan="1" rowspan="1">Serum</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

None referenced

# L. Test Principle:

When a sample containing ferritin is mixed with the Ferritin - LATEX reagent and the reaction buffer included in the kit, ferritin reacts with the antibodies leading to agglutination of the latex particles. The agglutination is detected as turbidity change (the decrease of transmitted light caused by the aggregates measured at $6 0 0 \mathrm { n m }$ ) and is directly proportional to the concentration of ferritin in the sample.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

A precision study was performed on an OLYMPUS AU640 Clinical Chemistry Analyzer using OLYMPUS ITA Control Levels (Low, Medium, and High). The within run, between run, and total $\% \mathrm { C V }$ were calculated according to CLSI (NCCLS) EP5-A protocol.

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=3>Within Run</td><td rowspan=1 colspan=3>Total</td></tr><tr><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>Level 3</td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>Level 3</td></tr><tr><td rowspan=1 colspan=1>Mean (ng/mL)</td><td rowspan=1 colspan=1>38.0</td><td rowspan=1 colspan=1>108.1</td><td rowspan=1 colspan=1>224.1</td><td rowspan=1 colspan=1>38.0</td><td rowspan=1 colspan=1>108.1</td><td rowspan=1 colspan=1>224.1</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>1.22</td><td rowspan=1 colspan=1>1.42</td><td rowspan=1 colspan=1>2.23</td><td rowspan=1 colspan=1>1.50</td><td rowspan=1 colspan=1>1.75</td><td rowspan=1 colspan=1>3.20</td></tr><tr><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>3.20</td><td rowspan=1 colspan=1>1.31</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>3.94</td><td rowspan=1 colspan=1>1.62</td><td rowspan=1 colspan=1>1.43</td></tr></table>

b. Linearity/assay reportable range:

Linearity was performed on an OLYMPUS AU640 Clinical Chemistry Analyzer according to CLSI (NCCLS) EP6-P Guideline. A serum sample with high Ferritin level was serially diluted and each of the 14 dilutions was assayed in quadruplicate on the Olympus AU 640. The acceptance criterion is $\pm 1 0 \%$ deviation from regression line. The percent deviation from the regression line for the 14 points ranged from -10.2 to $3 . 1 \%$ . The assay is linear over the reportable range of $4 { - } 4 5 0 \ \mathrm { n g / m l }$ .

Prozone Effect: High pool of Ferritin (SCIPAC) was diluted with saline. No hook effect was observed for the tested specimen at $1 0 { , } 0 0 0 \mathrm { n g / m l }$ compared to the upper limit of the measuring range of $4 5 0 ~ \mathrm { { n g / m L } }$ .

c. Traceability, Stability, Expected values (controls, calibrators, or methods): The recommended calibrator is standardized against the WHO $3 ^ { \mathrm { r d } }$ International Standard for ferritin, Recombinant NBSC code: 94/572.

d. Detection Limit:

The Lowest Detectable Level was defined as the Mean (20 replicates) $^ +$ 3SD $= 0 . 8 + 3 ( 0 . 9 ) = 3 . 4 \mathrm { n g / m L }$ . Detection Limit is stated at $4 . 0 \mathrm { n g / m L }$ .

Functional Lower Limit is estimated to be $4 . 0 \mathrm { n g / m L }$ . A serum with initial concentration value of $5 8 . 7 \mathrm { n g / m L }$ was serially diluted 1:1 with saline $( 0 . 9 \mathrm { g }$ $\mathrm { N a C l } / 1 0 0 \mathrm { m l } )$ .

e. Analytical specificity:

Interference: Interference testing was performed by spiking levels of each interferant into pooled serum. Acceptance criterion was set at $\leq \pm 1 0 \%$ (Final/Original results $\textbf { x l } 0 0 \%$ ).

Ascorbic Acid: Less than $5 \%$ up to $3 \mathrm { m g / d L }$ ascorbic acid   
• Hemolysis: Less than $5 \%$ up to $5 0 0 \mathrm { m g / d L }$ hemoglobin. Lipemia: Less than $10 \%$ up to $4 0 0 \mathrm { m g / d L }$ Intralipid $^ \mathrm { \textregistered }$ .   
• Icterus: Less than $5 \%$ up to $2 0 \mathrm { m g / d L }$ bilirubin. Rheumatoid Factor: Less than $5 \%$ up to $9 0 0 \mathrm { \ : I U / m l }$ RF.

f. Assay cut-off: Not applicable

2. Comparison studies:

a. Method comparison with predicate device: One hundred seventy-six (176) patient serum samples ranging from 7.50 - $4 9 1 . 4 0 ~ \mathrm { n g / m L }$ were analyzed using Ferritin-LATEX and Olympus Ferritin Reagent (predicate device) on an OLYMPUS AU 640 Clinical Chemistry Analyzer. No artificially prepared samples were used in this study. The following results were obtained using Linear Regression Analysis: $\mathrm { y } = 1 . 0 0 1 6 \mathrm { x } + 4 . 3 8 4 9 \mathrm { n g / m L }$ with a correlation coefficient of $\mathrm { R } = 0 . 9 9 5 8$ .

$b$ . Matrix comparison:

40 patient plasma (EDTA) ferritin samples ranging from $8 . 9 0 \mathrm { ~ - } 4 8 2 . 8 5 ~ \mathrm { n g / m L }$ were compared to serum ferritin values obtained using Medicon FerritinLATEX on an OLYMPUS AU 640 Clinical Chemistry Analyzer. The following results were obtained using Linear Regression Analysis: $\mathrm { y } = 0 . 9 8 4 7 \mathrm { x } - 1 . 1 2 7 5 \mathrm { n g / m L }$ , with a correlation coefficient of $\mathrm { R } { = } 0 . 9 9 7 8$ .

138 patient plasma (LiH) ferritin samples ranging from $5 . 6 - 4 7 7 . 5 0 \mathrm { n g / m L }$ were compared to serum ferritin values obtained using Medicon Ferritin

LATEX on an OLYMPUS AU 640 Clinical Chemistry Analyzer. The following results were obtained using Linear Regression Analysis: $\mathrm { y } = 0 . 9 7 7 8 \mathrm { x } + 1 . 2 8 8 6 \mathrm { n g / m L }$ , with a correlation coefficient of $\mathrm { R } { = } 0 . 9 9 8 8$

3. Clinical studies:

a. Clinical Sensitivity: Not determined   
$b$ . Clinical specificity: Not determined   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range: Reference ranges were taken from Tietz: 1. Tietz, NW, ed. Clinical Guide to Laboratory Tests. 3rd. ed Philadelphia: W.B. Saunders Company Ltd., 1995. 2. Burtis, CA and Ashwood, ER, ed. Tietz Textbook of Clinical Chemistry. 2nd. ed. Philadelphia: W.B. Saunders Company Ltd., 1994.

# Serum / Plasma:

Infants – 1 month: ${ 6 { \cdot } 4 0 0 \ n g / \mathrm { m L } }$   
1 month – 6 months: $6 { \cdot } 4 1 0 ~ \mathrm { \mathrm { n g / m L } }$   
6 months – 12 months: $\mathrm { 6 { - } 8 0 \ n g / m L }$   
1 year – 5 years: $6 { - } 6 0 ~ \mathrm { { n g / m L } }$   
6 years – 19 years: $6 { - } 3 2 0 ~ \mathrm { n g / m L }$   
Adult men: $2 0 { - } 2 5 0 \ \mathrm { n g / m L }$   
Adult women: $2 0 { - } 2 0 0 ~ \mathrm { n g / m L }$   
As stated in the product insert, each laboratory should determine its own expected values as dictated by GLP.

# N. Proposed Labeling:

The labeling is sufficient and satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.